வைரஸ் நோயெதிர்ப்பு நிபுணர் இல் வேட்டைக்காரன் மருத்துவ ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal
Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the nose and throat by up to 96%; also found to be effective against rhinovirus (common cold), the
predominant cause of the common cold and exacerbations of chronic respiratory diseases including asthma and COPD
Mode of action complementary to COVID-19 vaccines, once weekly nasal spray to play significant role in reducing COVID-19 community transmission and disease progression in at risk populations ....

New South Wales , Christophe Demaison , Caleb Hulme Moir , David Jackson , Nathan Bartlett , Ciara Byrne , Viral Immunologist At Hunter Medical Research Institute , Research Commercialisation Fund , Mana Communications , Department Of Microbiology , Biomedical Translation Fund , University Of Melbourne , Public Health England , Professor Miles Carroll At Public Health England , Peter Doherty Institute For Infection , European Respiratory Journal , Ena Respiratory , European Respiratory , Ena Respiratory Managing Director , Hunter Medical Research Institute , Associate Professor Nathan Bartlett , Associate Professor , Brandon Capital , Medical Research Commercialisation Fund , Australian Government , Translation Fund ,